Mycophenolate Mofetil Effective in Treatment of Neuromyelitis Optica

Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders
Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders
Mycophenolate mofetil effectively eliminated relapses in 60% of patients with neuromyelitis optica spectrum disorder.

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disorder of the central nervous system. Recently, various immunosuppressant medications were introduced as therapeutic options for preventing relapse of NMOSD. However, our understanding of the effectiveness of mycophenolate mofetil (MMF) in treating patients with NMOSD is based on only a small number of studies.

So-Young Huh, MD, of Kosin University College of Medicine in Busan, Korea, and colleagues evaluated the efficacy and safety of MMF treatment in 59 patients with NMOSD through a three-center retrospective review. 

READ FULL ARTICLE Curated publisher From